{"task_id": "269f6bf550e36b9e", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 201/464)", "text": "ed/matted axillary lymph\nnode(s)\n190\nBreast Cancer\n\n--- Page 212 ---\nTNM STAGING (CONT\u2019D)\n\u0002 cN2b=ipsilateral internal mammary nodes in\nthe absence of clinically evident axillary\nlymph node\n\u0002 pN2a=4 9 axillary lymph nodes\n\u0002 pN2b=ipsilateral internal mammary nodes in\nthe absence of clinically evident axillary\nlymph node\n\u0002 N3\n\u0002 cN3a=ipsilateral infraclavicular lymph node(s)\n\u0002 cN3b=ipsilateral internal mammary and axil\nlary lymph node(s)\n\u0002 cN3c=ipsilateral\nsupraclavicular\nlymph\nnode(s)\n\u0002 pN3a=10 or more axillary lymph nodes or\nmetastasis to the infraclavicular lymph\nnodes\n\u0002 pN3b=metastasis in clinically apparent ipsi\nlateral internal mammary lymph nodes in the\npresence of one or more positive axillary\nnode, or in >3 axillary lymph nodes and in\ninternal mammary lymph nodes with micro\nscopic disease detected by sentinel lymph\nnode dissection but not clinically apparent\n\u0002 pN3c=ipsilateral supraclavicular lymph node\nM stage (lungs, liver, bones, brain)\n\u0002 M1=distant metastasis. Micrometastasis early,\nrelatively slow growing, and variable course\nSTAGE GROUPINGS\nStage TNM @=any\n5 Year survival\nI\nT1N0M0\n100%\nIIA\nT0 1N1M0, T2N0M0\n90%\nIIB\nT2N1M0, T3N0M0\n80%\nIIIA\nT0 2N2M0, T3N1 2M0\n70%\nIIIB\nT4N0 2M0\n50%\nIIIC\nT@N3M0\n40%\nIV\nT@N@M1\n20%\nDIAGNOSTIC AND PROGNOSTIC ISSUES\nMAMMOGRAPHIC FINDINGS OF BREAST CAN\nCER\nspiculated, crab like, puckering lesions, archi\ntectural distortion, clustered microcalcifications\nSCREENING\nmonthly\nself breast\nexamination,\nannual clinical breast examination, annual mammo\ngram starting age 40\nPOOR\nPROGNOSTIC\nFACTORS\nyoung\nage,\nadvanced stage (especially nodal status and tumor\nsize), high grade, Her2/neu+, ER , PR , lymphatic/\nvascular invasion\nVAN NUYS PROGNOSTIC INDEX (VNPI)\nprovides\nthe risk of local recurrence after DCIS excision\n\u0002\nSIZE OF TUMOR\n1 \u000415 mm, 2=16 40 mm, 3\n>40 mm\n\u0002\nMARGIN\nWIDTH\n1 >10 mm, 2=1 10 mm, 3\n<1 mm\nDIAGNOSTIC AND PROGNOSTIC ISSUES (CONT\u2019D)\n\u0002\nGRADE\n1=non high grade, no comedo necrosis,\n2=non high grade with comedo necrosis, 3=high\ngrade with or without comedo necrosis\n\u0002\nAGE\n1 >60, 2=40 60, 3 <40 years old\n\u0002\nINTERPRETATION\nadd up the four factors\nVNPI\nscore\nRisk of\nrelapse\nTreatment\nrecommendation\n\u00046\nLow\nLumpectomy only\n7 9\nMod\nLumpectomy plus radiation\n\u000510\nHigh\nConsider mastectomy\nMANAGEMENT\nDCIS\n\u0002\nRESECTION\nbreast conserving surgery, plus adju\nvant radiation (if tumor >1 cm, comedo type, or\nclose margins <5 mm), or mastectomy if large\nlesions (>3 5 cm)\n\u0002\nADJUVANT HORMONAL\ntamoxifen may be consid\nered after breast conserving surgery for selected\nindividuals if ER/PR positive\nLCIS\n\u0002\nRESECTION\nobservation, breast conserving surgery\nor bilateral mastectomy for selected individuals\n\u0002\nHORMONAL\ntamoxifen or raloxifene may be used\nfor prevention of invasive breast cancer in selected\nindividuals\nSTAGE I AND II\n1. RESECTION\nbreast conserving surgery or mastect\nomy, plus sentinel biopsy or axillary lymph node\ndissection. If sentinel lymph node positive, pro\nceed to axillary dissection\n2. ADJUVANT SYSTEMIC THERAPY\nanthracycline \u0006 tax\nane (see below for details) \u0006 trastuzumab\n3. ADJUVANT RADIATION\nalways give adjuvant radia\ntion after breast conserving surgery. Adjuvant\nradiation should be considered after mastectomy\nif large tumor, skin involvement, muscle involve\nment, positive node, positive margins, or lympho\nvascular invasion\n4. ADJUVANT HORMONAL\ngive if ER/PR positive (see\nbelow for details)\nSTAGE III\n1. NEOADJUVANT\nSYSTEMIC\nTHERAPY\nanthracycline\nplus taxane (see below for details) \u0006 trastuzumab.\nAdjuvant therapy may also be considered if tumor\nresectable upfront\n2. RESECTION\nbreast conserving surgery or mastect\nomy, plus axillary lymph node dissection\n3. ADJUVANT\nRADIATION\nalmost always given for\nstage III disease\n4. ADJUVANT HORMONAL\ngive if ER/PR positive (see\nbelow for details)\nBreast Cancer\n191", "text_length": 3790, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 201/464)", "type": "chunk", "chunk_index": 200, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.522353", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.523149", "status": "complete", "chunks_added": 2}